Promotional Challenges and Considerations for Rare Disease Treatments
According to FDA statistics, over 7,000 rare diseases affect more than 30 million people in the US. The collective number of diseases is large, but the number of patients affected by each disease is small, resulting in smaller clinical datasets. This interactive session will engage attendees while exploring the role of advertising and promotion in reaching and engaging with rare disease patient advocacy groups, including ultra-rare diseases. Panelists will also address questions about implementing disease awareness campaigns without explicitly promoting specific drugs.
Bryant M. Godfrey, Partner, Foley Hoag LLP
Dominick Paul DiSabatino, Partner, Sheppard Mullin Richter & Hampton LLP
Moderated by Mark Gaydos, Vice President & Global Head, Advertising, Promotion & Labeling, Global Regulatory Affairs, Sanofi